AU-018
Heart-Safe Chemotherapy (Anthracycline-induced cardiotoxicity)
IND enablingPreclinical development
Key Facts
Indication
Heart-Safe Chemotherapy (Anthracycline-induced cardiotoxicity)
Phase
IND enabling
Status
Preclinical development
Company
About Auransa
Auransa is pioneering a biology-first AI platform that processes heterogeneous human disease data—including over 500,000 gene expression profiles across 70+ diseases—to rapidly identify novel drug candidates with high predictivity. The company has advanced its lead asset, AU-409, into Phase 1 clinical trials for liver cancer in the US and Asia, and is developing AU-018 to improve the safety of anthracycline chemotherapy. Led by a team with deep experience in genomics, data science, and drug discovery from major pharmaceutical companies, Auransa collaborates with leading pharma and academic institutions to translate its discoveries into meaningful patient benefits.
View full company profile